According to Wu's report, Nasdaq-listed company LIXTE Biotechnology announced that its board of directors has approved a strategic capital allocation plan to incorporate cryptocurrency into its corporate treasury assets. Under the new policy, LIXTE may allocate up to 25% of its corporate treasury funds to cryptocurrencies, including Bitcoin and other digital assets deemed suitable by the board. The specific timing and amount of purchases will be determined based on market conditions and company strategic considerations.